GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » 1-Year ROIIC %
中文

Verici Dx (Verici Dx) 1-Year ROIIC %

: 0.00% (As of Jun. 2023)
View and export this data going back to 2021. Start your Free Trial

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Verici Dx's 1-Year ROIIC % for the quarter that ended in Jun. 2023 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Verici Dx's 1-Year ROIIC % or its related term are showing as below:

VRCDF's 1-Year ROIIC % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -8.14
* Ranked among companies with meaningful 1-Year ROIIC % only.

Verici Dx 1-Year ROIIC % Historical Data

The historical data trend for Verici Dx's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
1-Year ROIIC %
- - -317.05

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
1-Year ROIIC % - - - -317.05 -

Competitive Comparison

For the Diagnostics & Research subindustry, Verici Dx's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx 1-Year ROIIC % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Verici Dx's 1-Year ROIIC % falls into.



Verici Dx 1-Year ROIIC % Calculation

Verici Dx's 1-Year ROIIC % for the quarter that ended in Jun. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -11.361 (Jun. 2023) - (Jun. 2022) )/( 4.847 (Jun. 2023) - 4.557 (Jun. 2022) )
=/0.29
=0.00%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Verici Dx  (OTCPK:VRCDF) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Verici Dx 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Verici Dx's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines